Vittore Cereda

1.7k total citations
30 papers, 1.3k citations indexed

About

Vittore Cereda is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Vittore Cereda has authored 30 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Vittore Cereda's work include Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (11 papers) and Prostate Cancer Treatment and Research (6 papers). Vittore Cereda is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (11 papers) and Prostate Cancer Treatment and Research (6 papers). Vittore Cereda collaborates with scholars based in Italy, United States and Hong Kong. Vittore Cereda's co-authors include Jeffrey Schlom, James L. Gulley, Philip M. Arlen, Mario Roselli, Vincenzo Formica, Junko Yokokawa, Cinzia Remondo, Fiorella Guadagni, William L. Dahut and Kwong-Yok Tsang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Vittore Cereda

29 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vittore Cereda Italy	18	859	733	352	305	104	30	1.3k
Carmen Oñate Spain	12	1.0k 1.2×	1.1k 1.5×	354 1.0×	197 0.6×	102 1.0×	19	1.7k
Italia Grenga United States	20	1.1k 1.3×	617 0.8×	326 0.9×	337 1.1×	157 1.5×	43	1.6k
Atsushi Nakamura Japan	16	800 0.9×	255 0.3×	246 0.7×	567 1.9×	108 1.0×	100	1.4k
Gigliola Reato Italy	18	542 0.6×	262 0.4×	484 1.4×	175 0.6×	86 0.8×	36	1.4k
Davis Y. Torrejon United States	10	1.4k 1.6×	924 1.3×	487 1.4×	463 1.5×	109 1.0×	16	2.0k
France Bourdeau Canada	13	735 0.9×	1.4k 1.9×	453 1.3×	205 0.7×	118 1.1×	21	2.0k
Stephen Gowing Canada	9	575 0.7×	971 1.3×	333 0.9×	234 0.8×	177 1.7×	18	1.6k
James Strauss United States	14	394 0.5×	370 0.5×	224 0.6×	88 0.3×	103 1.0×	69	837
Saleh Rachidi United States	16	544 0.6×	305 0.4×	454 1.3×	105 0.3×	112 1.1×	27	1.2k
Eva Emmell United States	12	237 0.3×	371 0.5×	297 0.8×	101 0.3×	63 0.6×	18	1.0k

Countries citing papers authored by Vittore Cereda

Since Specialization

Citations

This map shows the geographic impact of Vittore Cereda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vittore Cereda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vittore Cereda more than expected).

Fields of papers citing papers by Vittore Cereda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vittore Cereda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vittore Cereda. The network helps show where Vittore Cereda may publish in the future.

Co-authorship network of co-authors of Vittore Cereda

This figure shows the co-authorship network connecting the top 25 collaborators of Vittore Cereda. A scholar is included among the top collaborators of Vittore Cereda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vittore Cereda. Vittore Cereda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cereda, Vittore & Mario D’Andrea. (2025). Pancreatic cancer: failures and hopes—a review of new promising treatment approaches. Exploration of Targeted Anti-tumor Therapy. 6. 1002299–1002299. 2 indexed citations

Cereda, Vittore, et al.. (2024). Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials. SHILAP Revista de lepidopterología. 5(5). 997–1010. 1 indexed citations

Cereda, Vittore, et al.. (2020). Hormonal prostate cancer therapies and cardiovascular disease: a systematic review. Heart Failure Reviews. 27(1). 119–134. 11 indexed citations

Cereda, Vittore, Vincenzo Formica, & Mario Roselli. (2018). Issues and promises of bevacizumab in prostate cancer treatment. Expert Opinion on Biological Therapy. 18(6). 707–717. 21 indexed citations

Roselli, Mario, Vincenzo Formica, Vittore Cereda, et al.. (2016). The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. OncoImmunology. 5(7). e1188243–e1188243. 25 indexed citations

Formica, Vincenzo, David Cunningham, Elizabeth Smyth, et al.. (2014). Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Medical Oncology. 31(9). 166–166. 48 indexed citations

Cereda, Vittore, et al.. (2014). Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. Expert Opinion on Investigational Drugs. 23(4). 469–487. 16 indexed citations

Roselli, Mario, Vittore Cereda, Vincenzo Formica, et al.. (2013). Effects of conventional therapeutic interventions on the number and function of regulatory T cells. OncoImmunology. 2(10). e27025–e27025. 142 indexed citations

Formica, Vincenzo, Vittore Cereda, Italia Grenga, et al.. (2013). Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). Medical Oncology. 30(4). 743–743. 19 indexed citations

10.

Cereda, Vittore, Matteo Vergati, Ngar‐Yee Huen, et al.. (2011). Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. Vaccine. 29(31). 4992–4999. 17 indexed citations

11.

Vergati, Matteo, Vittore Cereda, Ravi A. Madan, et al.. (2010). Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunology Immunotherapy. 60(2). 197–206. 46 indexed citations

12.

Cereda, Vittore, Diane J. Poole, Claudia Palena, et al.. (2009). New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunology Immunotherapy. 59(1). 63–71. 29 indexed citations

13.

Gulley, James L., Philip M. Arlen, Ravi A. Madan, et al.. (2009). Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunology Immunotherapy. 59(5). 663–674. 218 indexed citations

14.

Gulley, James L., Philip M. Arlen, Kwong-Yok Tsang, et al.. (2008). Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma. Clinical Cancer Research. 14(10). 3060–3069. 176 indexed citations

15.

Lechleider, Robert J., Philip M. Arlen, Kwong-Yok Tsang, et al.. (2008). Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant. Clinical Cancer Research. 14(16). 5284–5291. 78 indexed citations

16.

Remondo, Cinzia, Vittore Cereda, Sven Mostböck, et al.. (2008). Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. Vaccine. 27(7). 987–994. 47 indexed citations

17.

Masuelli, Laura, Chiara Focaccetti, Vittore Cereda, et al.. (2007). Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.. PubMed. 30(2). 381–92. 31 indexed citations

18.

Yokokawa, Junko, Tapan K. Bera, Claudia Palena, et al.. (2007). Identification of cytotoxic T‐lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). International Journal of Cancer. 121(3). 595–605. 15 indexed citations

19.

Bei, Roberto, D. Mentuccia, Paola Trono, et al.. (2006). Immunity to Extracellular Matrix Antigens is Associated with Ultrastructural Alterations of the Stroma and Stratified Epithelium Basement Membrane in the Skin of Hashimoto's Thyroiditis Patients. International Journal of Immunopathology and Pharmacology. 19(3). 661–673. 23 indexed citations

20.

Bei, Roberto, Alfredo Budillon, Laura Masuelli, et al.. (2004). Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. The Journal of Pathology. 204(3). 317–325. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact